Douglas Rex

from the Oslo Group and others.

One is the Nordic update study in Lancet and the other one is the surveillance EPOS trial published in the New England Journal and we also had some comments from Douglas Rex.

So David, starting with primary screening, of course it's not in the empty space.

It depends on the country's logistics and economic possibilities and interests.

On the day of the appearance of your New England paper, congratulations.

And we'll have comments and further podcasts on the study with Douglas Rex and David Weinberg in the coming days.

Thank you very much for watching.

Thank you.

But very nice people also.

Stu Sherman, Doug Rex was there.

An enormous continuity of people.

Yeah, so I guess I'm the black sheep in the family.

But yeah, it started out with Glenn.

Doug Rex was in my medical school class.

Interestingly, he was sort of encouraged to do a year of basic science.

The division director at that time wanted Doug to become a basic scientist and he went off to Purdue and did some molecular some molecular biology work and then came back and just said I don't want to do this I want to be a clinician but Doug had stayed around Stu Sherman stayed you know for a long time he was not he didn't grow up in the IU system but he came as an advanced fellow and then came back and And so there has been great continuity.